First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis.

Purpose: The purpose of this study is to evaluate the pharmacokinetics, immunogenicity, safety, and tolerability of guselkumab, a human monoclonal antibody with high affinity and specificity for binding to interleukin-23. Methods: In this first-in-human, phase 1, randomized study, a single intraveno...

Full description

Bibliographic Details

Published in:	European Journal of Clinical Pharmacology Vol. 72; no. 11; pp. 1303 - 1311
Main Authors:	Zhuang, Yanli, Calderon, Cesar, Marciniak, Stanley, Bouman-Thio, Esther, Szapary, Philippe, Yang, Tong-Yuan, Schantz, Allen, Davis, Hugh, Zhou, Honghui, Xu, Zhenhua
Format:	clinical trial research tables/charts Journal Article
Published:	Springer Nature Nov2016
Online Access:	View this record in EBSCOhost